FELBAMATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1993)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: N03AX10
UNII: X72RBB02N8

Structure
InChI Key WKGXYQFOCVYPAC-UHFFFAOYSA-N
Smile NC(=O)OCC(COC(N)=O)c1ccccc1
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

Physicochemical Descriptors

Property Name Value
Molecular Formula C11H14N2O4
Molecular Weight 238.24
AlogP 0.96
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 5.0
Polar Surface Area 104.64
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 17.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Glutamate [NMDA] receptor antagonist FDA ISBN PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Ligand-gated ion channel Ionotropic glutamate receptor NMDA receptor
- - - - 61-90

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Bipolar Disorder 2 D001714 ClinicalTrials

Related Entries

MCS

Side Effects from Label

Side effects Relative Frequency (%) Labels
General disorders and administration site conditions Decreased appetite 54.8
Nervous system disorders Somnolence 48.4
Infections and infestations Upper respiratory tract infection 45.2
Gastrointestinal disorders Vomiting 38.7
Nervous system disorders Headache 36.8
Gastrointestinal disorders Nausea 34.2
Infections and infestations Upper respiratory tract infection
Investigations Body temperature increased 22.6
General disorders and administration site conditions Decreased appetite 19.3
Nervous system disorders Somnolence 19.3
Nervous system disorders Headache
Psychiatric disorders Nervousness
Psychiatric disorders Tension
Cardiac disorders Dizziness 18.4
Nervous system disorders Headache 18.0
Nervous system disorders Insomnia 17.5
General disorders and administration site conditions Asthenia 16.8
General disorders and administration site conditions Fatigue 16.8
Gastrointestinal disorders Vomiting 16.7
Nervous system disorders Insomnia 16.1
Psychiatric disorders Nervousness 16.1
Psychiatric disorders Tension 16.1
General disorders and administration site conditions Decreased appetite
Nervous system disorders Insomnia
Gastrointestinal disorders Vomiting
Cardiac disorders Dizziness
Gastrointestinal disorders Constipation 12.9
Blood and lymphatic system disorders Purpura 12.9
Blood and lymphatic system disorders Vascular purpura 12.9
Gastrointestinal disorders Dyspepsia 12.3
Gastrointestinal disorders Constipation 11.4
Investigations Body temperature increased
Nervous system disorders Somnolence
General disorders and administration site conditions Asthenia 9.7
Skin and subcutaneous tissue disorders Dermatitis 9.7
General disorders and administration site conditions Fatigue 9.7
General disorders and administration site conditions Gait disturbance 9.7
Gastrointestinal disorders Hiccups 9.7
Ear and labyrinth disorders Otitis media 9.7
Gastrointestinal disorders Pharyngitis 9.7
Skin and subcutaneous tissue disorders Rash 9.7
Nervous system disorders Headache
Gastrointestinal disorders Dyspepsia 8.6
Nervous system disorders Insomnia 8.6
Infections and infestations Upper respiratory tract infection 8.6
Gastrointestinal disorders Vomiting 8.6
Skin and subcutaneous tissue disorders Dermatitis
Blood and lymphatic system disorders Purpura
Skin and subcutaneous tissue disorders Rash
Nervous system disorders Urinary incontinence
Blood and lymphatic system disorders Vascular purpura
General disorders and administration site conditions Asthenia
Gastrointestinal disorders Dyspepsia
General disorders and administration site conditions Fatigue
Nervous system disorders Insomnia
Psychiatric disorders Nervousness 7.0
Nervous system disorders Somnolence
Psychiatric disorders Tension 7.0
Infections and infestations Upper respiratory tract infection
General disorders and administration site conditions Asthenia 6.9
Gastrointestinal disorders Constipation 6.9
General disorders and administration site conditions Fatigue 6.9
Nervous system disorders Headache 6.9
Infections and infestations Rhinitis 6.9
Psychiatric disorders Affect lability 6.5
Nervous system disorders Ataxia 6.5
Respiratory, thoracic and mediastinal disorders Cough 6.5
Gastrointestinal disorders Dyspepsia 6.5
Nervous system disorders Headache 6.5
Blood and lymphatic system disorders Leukopenia 6.5
Social circumstances Mental disability 6.5
Eye disorders Miosis 6.5
Psychiatric disorders Mood swings 6.5
Gastrointestinal disorders Nausea 6.5
General disorders and administration site conditions Pain 6.5
Nervous system disorders Thinking abnormal 6.5
Nervous system disorders Urinary incontinence 6.5
Investigations Weight decreased 6.5
Eye disorders Diplopia 6.1
Gastrointestinal disorders Dysgeusia 6.1
Nervous system disorders Tremor 6.1
Gastrointestinal disorders Abdominal pain 5.3
Psychiatric disorders Anxiety 5.3
Psychiatric disorders Depression 5.3
Gastrointestinal disorders Diarrhoea 5.3
General disorders and administration site conditions Gait disturbance 5.3
Gastrointestinal disorders Gastrointestinal pain 5.3
Infections and infestations Upper respiratory tract infection 5.3
Eye disorders Visual impairment 5.3
Investigations Alanine aminotransferase increased 5.2
Psychiatric disorders Anxiety 5.2
Gastrointestinal disorders Diarrhoea 5.2
Psychiatric disorders Anxiety
Investigations Body temperature increased
Skin and subcutaneous tissue disorders Dermatitis
Skin and subcutaneous tissue disorders Rash
Gastrointestinal disorders Vomiting
General disorders and administration site conditions Asthenia 4.0
Eye disorders Diplopia 4.0
General disorders and administration site conditions Fatigue 4.0
Nervous system disorders Insomnia 4.0
Infections and infestations Upper respiratory tract infection 4.0
General disorders and administration site conditions Asthenia
Nervous system disorders Ataxia
Gastrointestinal disorders Dyspepsia
General disorders and administration site conditions Fatigue
Gastrointestinal disorders Hiccups
Social circumstances Mental disability
Gastrointestinal disorders Pharyngitis
Nervous system disorders Thinking abnormal
Investigations Alanine aminotransferase increased 3.5
Nervous system disorders Ataxia 3.5
Skin and subcutaneous tissue disorders Dermatitis 3.5
Nervous system disorders Paraesthesia 3.5
Skin and subcutaneous tissue disorders Rash 3.5
Infections and infestations Sinusitis 3.5
Skin and subcutaneous tissue disorders Acne 3.4
Skin and subcutaneous tissue disorders Dermatitis 3.4
Eye disorders Diplopia 3.4
General disorders and administration site conditions Face oedema 3.4
Investigations Haemoglobin 3.4
Vascular disorders Haemorrhage 3.4
Metabolism and nutrition disorders Hypophosphataemia 3.4
Ear and labyrinth disorders Otitis media 3.4
Skin and subcutaneous tissue disorders Rash 3.4
Infections and infestations Urinary tract infection 3.4
Investigations Weight decreased 3.4
Investigations Body temperature increased 2.6
Cardiac disorders Chest pain 2.6
Nervous system disorders Depressed level of consciousness 2.6
Gastrointestinal disorders Dry mouth 2.6
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 2.6
Musculoskeletal and connective tissue disorders Myalgia 2.6
Gastrointestinal disorders Pharyngitis 2.6
Nervous system disorders Stupor 2.6
Gastrointestinal disorders Constipation
General disorders and administration site conditions Decreased appetite
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Nausea
Psychiatric disorders Nervousness
Nervous system disorders Paraesthesia
Psychiatric disorders Tension
Nervous system disorders Tremor
Eye disorders Visual impairment
Investigations Alanine aminotransferase increased 2.0
Psychiatric disorders Anxiety 2.0
Gastrointestinal disorders Constipation 2.0
Gastrointestinal disorders Dyspepsia 2.0
Infections and infestations Urinary tract infection 2.0
Gastrointestinal disorders Vomiting 2.0
General disorders and administration site conditions Decreased appetite 1.6
Gastrointestinal disorders Nausea 1.4
Skin and subcutaneous tissue disorders Dermatitis 1.2
Skin and subcutaneous tissue disorders Rash 1.2
Skin and subcutaneous tissue disorders Dermatitis 1.1
Skin and subcutaneous tissue disorders Rash 1.1
Investigations Weight decreased 1.1

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
24.63
General disorders and administration site conditions
15.08
Injury, poisoning and procedural complications
9.68
Gastrointestinal disorders
8.78
Psychiatric disorders
7.97
Musculoskeletal and connective tissue disorders
4.32
Investigations
4.14
Metabolism and nutrition disorders
3.65
Respiratory, thoracic and mediastinal disorders
3.24
Infections and infestations
2.97
Blood and lymphatic system disorders
2.16

Cross References

Resources Reference
CAS NUMBER 25451-15-4
ChEBI 4995
ChEMBL CHEMBL1094
DrugBank DB00949
DrugCentral 1140
EPA CompTox DTXSID9023041
FDA SRS X72RBB02N8
Human Metabolome Database HMDB0015084
Guide to Pharmacology 5473
KEGG C07501
PharmGKB PA449590
PubChem 3331
SureChEMBL SCHEMBL34947
ZINC ZINC000001530803
CONTENTS